Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial (Q38283828)

1 September 2017

1 reference

title

Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial (English)

1 reference

chronic lymphocytic leukemia

1 September 2017

0 references

1 reference

1 reference

Stefano Molica

1

1 reference

PubMed ID

25479582

1 September 2017

language of work or name

1 reference

5 December 2014

1 reference

Expert Review of Anticancer Therapy

1 September 2017

1 reference

1 September 2017

15

1 reference

1 September 2017

1

1 reference

1 September 2017

9-15

1 reference

Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment

1 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Obinutuzumab for B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Validation of the Cumulative Illness Rating Scale in a geriatric residential population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Highlights in the treatment of chronic lymphocytic leukemia from the 2013 meeting of the American Society of Hematology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.990442

10.1586/14737140.2015.990442

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference

PubMed ID

25479582